Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/18166
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nadebaum, David P | - |
dc.contributor.author | Lee, Sze Ting | - |
dc.contributor.author | Nikfarjam, Mehrdad | - |
dc.contributor.author | Scott, Andrew M | - |
dc.date.accessioned | 2018-08-08T01:03:19Z | - |
dc.date.available | 2018-08-08T01:03:19Z | - |
dc.date.issued | 2018-07 | - |
dc.identifier.citation | World Journal of Nuclear Medicine 2018; 17(3): 195-197 | - |
dc.identifier.issn | 1450-1147 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/18166 | - |
dc.description.abstract | 68Ga-DOTATATE positron emission tomography (PET) is a molecular imaging technology which has shown superiority over 111In-octreotide scanning for the detection and staging of neuroendocrine tumors. We report three patients with pancreatic masses that were ultimately diagnosed as clear cell renal cell carcinoma (ccRCC) metastases on histopathology. During their initial diagnostic assessment, the three patients underwent both 18F-fluorodeoxyglucose (18F-FDG) and 68Ga-DOTATATE PET. While all three patients' lesions showed variable 18F-FDG avidity, uptake on 68Ga-DOTATATE PET was comparatively intense. The small case series illustrates the need to consider ccRCC in the differential diagnosis of 68Ga-DOTATATE avid lesions. | - |
dc.language.iso | eng | - |
dc.subject | 68Ga-DOTATATE | - |
dc.subject | kidney neoplasms | - |
dc.subject | positron emission tomography | - |
dc.subject | renal cell carcinoma | - |
dc.subject | somatostatin receptors | - |
dc.title | Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | World Journal of Nuclear Medicine | - |
dc.identifier.affiliation | Department of Molecular Imaging and Therapy, Austin Health, the University of Melbourne, Heidelberg, Victoria, Australia | - |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, La Trobe University, Melbourne, Victoria, Australia | - |
dc.identifier.affiliation | Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia | - |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | - |
dc.identifier.doi | 10.4103/wjnm.WJNM_38_17 | - |
dc.identifier.orcid | 0000-0001-8641-456X | - |
dc.identifier.orcid | 0000-0003-4866-276X | - |
dc.identifier.orcid | 0000-0002-6656-295X | - |
dc.identifier.pubmedid | 30034285 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Lee, Sze Ting | |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Surgery (University of Melbourne) | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.